 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Xeris Biopharma Reports Third Quarter 2023 Financial Results

Investors eyeing a purchase of Xeris Biopharma Holdings Inc (XERS) stock, but cautious about paying the going market price of 1.97/share, might benefit from considering selling puts among the...

Commit To Purchase Xeris Biopharma Holdings At $1.50, Earn 16.9% Annualized Using Options

Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing innovative products across a range...

Xeris Biopharma Announces Private Convertible Note Exchange Transactions

Xeris to Participate in the 2023 Cantor Global Healthcare Conference

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside...

Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter and six months ended June 30...

Xeris Biopharma Reports Second Quarter 2023 Financial Results

Xeris Biopharma achieves record 2Q revenue and tightens full-year guidance

Investors eyeing a purchase of Xeris Biopharma Holdings Inc (XERS) stock, but tentative about paying the going market price of 2.58/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January ...

Commit To Buy Xeris Biopharma Holdings At $1.50, Earn 14.8% Annualized Using Options

Xeris Biopharma Holdings, Inc. (XERS) Q2 2023 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Watchers	10,148
52-Wk Low	$0.9701
52-Wk High	$3.07

Market Cap	$266.58M
Volume (M)	1.31M
52-Wk High	$3.07
52-Wk Low	$0.9701

Period	Estimated	Reported	Surprise	Result
Q3'23	$-0.10	$-0.09	13.94%	BEAT
Q2'23	$-0.12	$-0.14	-21.74%	MISSED
Q1'23	$-0.16	$-0.12	23.81%	BEAT
Q4'22	$-0.15	$-0.10	32.73%	BEAT
Q3'22	$-0.15	$-0.16	-3.41%	MISSED

XERS Xeris Biopharma Holdings Inc

About

Feed

News

Sentiment

Earnings

Fundamentals